Fuso Pharmaceutical Industries (4538) · TargetFirst stated

Growth Investment in Research and Development and Productivity Improvements Through Fiscal 2030

First written in FY2026. . Latest entry: FY2026.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Establishment of a growth investment allocation under the medium-term management planA theme 129 companies write about · 0 as a headwind · 139 as a tailwind

15 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Showing 14 of the 129 companies compared. The sentences above are computed from all 129.

Full recordFilings, disclosures and news, newest first

FY2026First statedAnnual report
「The Company will implement a clear capital allocation policy to improve profitability through growth investments of at least ¥16 billion in research and development and at least ¥24 billion in productivity improvements through fiscal 2030, while enhancing capital efficiency by reducing its holdings of fixed assets and policy-held shares.」
The Company established a capital allocation policy involving the reduction of fixed assets and policy-held shares, along with growth investments of at least ¥16 billion in research and development and at least ¥24 billion in productivity improvements through fiscal 2030.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for Fuso Pharmaceutical Industries yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.